Prevention and Treatment of Postphlebitic Syndrome

Results of a 3-Part Study

Jeffrey S. Ginsberg, MD; Jack Hirsh, MD; James Julian, MMath; Mary Vander LaandeVries, RN; Deborah Magier, RN; Betsy MacKinnon, MSc; Michael Gent, DSc

Background: The true incidence of postphlebitic syndrome (PPS) following proximal deep venous thrombosis (DVT) and the efficacy of graduated compression stockings in preventing and treating PPS are unknown.

Methods: A 3-part study of 202 patients evaluated 1 year after proximal DVT: 2 randomized placebo-controlled trials of stockings and 1 prospective cohort of untreated patients. Patients were evaluated for PPS, using a standardized questionnaire, and for venous valvular incompetence, using photoplethysmography and venous Doppler. They were enrolled in study 1 or study 2 if they did not have symptomatic PPS and did not have or had venous valvular incompetence, respectively, and into study 3 if they had symptomatic PPS. Study 1 patients were left untreated and followed up for development of PPS every 6 months for a mean of 55 months. Study 2 patients were randomized to a below-knee stocking (20-30 mm Hg) or a matched placebo stocking, and followed up for development of PPS every 6 months for a mean of 57 months. Study 3 patients were randomized to an active stocking (30-40 mm Hg) or a matched placebo stocking and followed up every 3 months for treatment failure, defined a priori.

Results: In study 1, 6 (5.0%) of 120 patients were categorized as treatment failures, a rate similar to placebo-treated study 2 patients (P=.10). In study 2, 0 (0%) of 24 active and 1 (4.3%) of 23 placebo-treated patients were categorized as treatment failures (P=.49). In study 3, 11 (61.1%) of 18 active and 10 (58.8%) of 17 placebo-treated patients were categorized as treatment failures (P>.99).

Conclusions: Most patients do not have PPS 1 year after proximal DVT, and do not require stockings. We failed to show a benefit of stockings in patients with PPS, but the small numbers preclude definitive conclusions.

Arch Intern Med. 2001;161:2105-2109

Deep vein thrombosis (DVT) is a relatively common disease that can be associated with pulmonary embolism, an acute complication, as well as the postphlebitic syndrome (PPS), a chronic complication. Rapid identification of DVT and treatment with anticoagulants virtually eliminates the risk of pulmonary embolism. However, prevention and treatment of the PPS, which consists of chronic pain and swelling and, occasionally, ulceration of the leg, are problematic because anticoagulant therapy alone might not be effective, and there are few well-designed clinical trials to provide guidelines.

Patients with acute DVT usually present with pain and swelling due to venous obstruction and inflammation caused by the thrombus. Once anticoagulant therapy is initiated, venous obstruction usually resolves over several months due to recanalization and development of collateral venous channels, leading to initial improvement in pain and swelling. However, over time, it is believed that venous valvular incompetence, produced when thrombosed venous segments recanalize, can cause venous hypertension, which in turn can result in recurrence of pain and swelling; this is typical of the PPS. It is probable that venous valvular incompetence precedes, and is a sine qua non for, the PPS, although not all patients with venous valvular incompetence become symptomatic.

In general, 2 approaches have been used in the prevention and treatment of the PPS: thrombolytic therapy and graduated compression stockings. Thrombolytic therapy has the potential to prevent morbidity from the PPS by lysing thrombi, thereby relieving acute obstruction and preventing the venous valvular damage and the residual venous obstruction that cause venous hypertension. However, clinical trials have not clearly shown that thrombolytic therapy reduces the incidence of the PPS and it is unsuitable in most patients either because of the risk (eg, postoperative patients) or because it is unlikely to be effective due to the thrombus age.

Graduated compression stockings are considered to be the mainstay of therapy for PPS and are often routinely applied to patients shortly after a diagnosis of DVT is made. By counteracting venous hyper-
PATIENTS AND METHODS

The study was approved by the institutional review board of the participating McMaster University–based hospitals, Hamilton. Informed consent was obtained from all patients after the study was explained.

INTERVENTION

Patients who had presented with a first episode of objectively confirmed proximal (involving the popliteal or more proximal vein) DVT to a McMaster University–affiliated hospital were screened for eligibility into the study 1 year after their DVT. Patients were subdivided into those who presented with suspected symptomatic DVT and those who had DVT found on routine venography after major orthopedic surgery. The latter group consisted primarily of subjects enrolled in 1 of several trials of DVT prophylaxis. The presence of 1 or more of the following excluded patients from the study: (1) previous graduated compression stocking therapy, (2) geographic inaccessibility, and (3) failure to provide informed consent. If eligible and consenting, patients were evaluated with a standardized questionnaire to determine if they had clinical evidence of PPS, and objective testing to determine if they had evidence of venous valvular incompetence. Depending on the findings, they were enrolled in 1 of 3 studies.

DEFINITION OF PPS

There is no uniformly accepted definition of PPS. Intermittent and reversible pain and swelling can be seen acutely with DVT and for weeks and even months afterward, particularly when the patient becomes mobile. Thus, we believed it was important to allow the early reversible symptoms to subside before labeling a patient as having PPS. Therefore, a priori, we used the following definition of PPS: chronic (>1 month in duration), typical (better after a night’s sleep and leg elevation, worse at the end of the day and after prolonged standing or sitting), and pain and swelling of the leg(s) 6 months or more after a proximal DVT. Patients were categorized as having PPS only if they had both pain and swelling.

To test a management strategy to reduce morbidity from PPS and delineate the role of stockings in the prevention and treatment of PPS, we conducted a 3-part study. Patients were seen 1 year after proximal DVT and asked about symptoms of PPS and evaluated for venous valvular incompetence.

Thus, we carried out 2 randomized placebo-controlled trials and 1 cohort study, for which we had 3 primary objectives: (1) to determine in asymptomatic patients if the presence of normal valvular function predicts lack of subsequent morbidity from the PPS, without the need for stockings (study 1); (2) to determine if asymptomatic patients with objective evidence of venous valvular incompetence are predisposed to the development of PPS and, if so, whether therapy with graduated compression stockings prevents or delays the onset of PPS (study 2); and (3) to determine if therapy with graduated compression stockings in patients with PPS following DVT is effective in reducing symptoms (study 3).

The study began in July 1990 and the last patient completed follow-up in December 1999. During the study period, 384 patients were screened for eligibility and

RESULTS
(see definition above) and stocking compliance. Stockings were replaced at each 6-month follow-up. Patients who developed symptoms of PPS were considered to be treatment failures.

Patients enrolled in study 3 were allocated, in a randomized double-blind trial, to either a graduated compression stocking with a pressure of 30 to 40 mm Hg or a matched placebo stocking with no hemodynamic effect (1 to 2 sizes too large). Patients with symptoms in the calf only received a “below-knee” stocking, and those with thigh symptoms received a “thigh-length” stocking. Only the symptomatic leg(s) was treated. Prerandomization stratification for patients with calf symptoms vs those with symptoms above the knee was done to ensure balanced randomization. Patients were encouraged to wear the stockings as much as possible during waking hours. A baseline assessment was performed and then patients were seen every 3 months for the duration of the study. The stockings were replaced every 3 months.

Patients in study 3 were considered to be treatment failures under any of the following circumstances:
1. The patient felt that the pain and/or swelling did not improve or was worse after the first 3-month treatment interval—further defined as the patient answering a global rating questionnaire (Figure 2) that they were worse or about the same.
2. The patient experienced symptomatic deterioration during any 2 consecutive treatment intervals—further defined as the patient answering the global rating questionnaire that they were worse in 2 consecutive intervals.
3. The patient experienced marked symptomatic deterioration during any treatment interval—further defined as the patient answering question 1 of the global rating questionnaire that they were worse and question 2 with answers e, f, or g (ie, a good deal, a great deal, or very great deal worse, respectively).
4. Symptoms caused 5 or more days of work absenteeism or inability to perform housework during any 3-month interval.
5. The patient developed a venous ulcer.

AVOIDANCE OF BIAS AND CONTAMINATION

Blinding was maintained by removing labels from stockings and by having patients remove their stockings before their 3- to 6-month assessments. To avoid interviewer bias, patients in study 1 were instructed not to inform the interviewer that they were not using stockings.

STATISTICAL CONSIDERATIONS

Analysis

For study 1, the primary analysis was a description of the incidence of treatment failure (and the 95% confidence interval [CI]). A secondary analysis comprised a comparison of the proportions of treatment failures in study 1 patients with the placebo arm of study 2 patients. For both study 2 and study 3, the primary analysis was a comparison of the proportion of treatment failures in the 2 arms of the study.

The occurrence of symptoms was treated in the context of survival analysis and the treatment failure-free survival of the treatment groups was estimated by the Kaplan-Meier method and compared by the Mantel-Haenszel test. Patients who died or were otherwise lost to follow-up and had not developed PPS were considered as event-free up to the time of the last visit. Proportions were compared using the Fisher exact test. Odds ratios as well as proportions and their corresponding exact 95% CIs were calculated where indicated.

Sample Size

For study 1, we hypothesized that asymptomatic patients without venous valvular incompetence would have a risk of developing PPS of no more than 20% within 2 to 3 years. Using the placebo-treated patients in study 2 as the control group (treatment failure rate of 50% vs 20%) and accepting a 2-sided \( \alpha \) of .05 and a \( \beta \) error of .2, we estimated requiring a sample size of 46 patients. For study 2, we hypothesized that patients without symptoms but with venous valvular incompetence 1 year after proximal DVT would have a risk of developing PPS (treatment failure rate of approximately 50% within 2 to 3 years) if left untreated and that active stockings would reduce this to approximately 20%. Therefore, allowing a 2-sided \( \alpha \) of .05 and a \( \beta \) error of .2, we estimated requiring a sample size of 46 subjects per group. For study 3, we estimated that 30% of patients would be classified as treatment failures with the active stocking and that 30% would be treatment failures with the placebo stocking within 2 years. Accepting a 2-sided \( \alpha \) of .05 and a \( \beta \) error of .2, the estimated sample size was 25 patients per group.
asymptomatic at this time, they have a very low incidence of subsequent PPS.

Of the patients in study 3, 11 (61.1%) of 18 treated with active stockings were considered treatment failures compared with 10 (58.8%) of 17 treated with placebo stockings (P > .99). The 95% CI on the observed difference of 2.3% in the rates of treatment failure is −29% to +34%, meaning we cannot exclude a true, absolute benefit of stockings of almost 30%.

Of the 110 patients who were known to have originally presented with symptomatic DVT, 30 (27%) had PPS at 1 year and were randomized into study 3. In contrast, of the 82 patients who were known to have originally presented with asymptomatic DVT (usually found on routine, predischarge venography after orthopedic surgery), 3 (4%) had PPS and were randomized into study 3. This difference in the incidence of PPS is statistically significant (odds ratio, 9.9; 95% CI, 2.7-43.0; P < .001).

**COMMENT**

Based on the results of our studies, 3 important conclusions can be made. First, most patients (83%) do not have PPS 1 year after proximal DVT and they rarely develop it within 5 years or more after the diagnosis of DVT if they are asymptomatic at 1 year. Second, patients who develop asymptomatic DVT have a very low incidence of PPS (3/82 = 3.7%; 95% CI, 0.8%-10.3%) at 1 year. In contrast, patients with symptomatic DVT have a statistically and clinically significant increase in the incidence of PPS (30/110 = 27.3%; 95% CI, 18.9%-35.6%). Third, in all patients

---

**Postphlebitic Syndrome Studies**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Study 1: Asymptomatic PPS, No VVI, No Stocking</th>
<th>Study 2: Asymptomatic PPS, VVI</th>
<th>Study 3: Symptomatic PPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asymptomatic PPS, No VVI, No Stocking</td>
<td>Active (20-30 mm Hg GCS)</td>
<td>Active (30-40 mm Hg GCS)</td>
</tr>
<tr>
<td>No. of patients</td>
<td>120</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>Age, mean (range), y</td>
<td>64.0 (25-91)</td>
<td>62.0 (33-78)</td>
<td>60.5 (24-87)</td>
</tr>
<tr>
<td>Sex, % female (No.)</td>
<td>56 (67)</td>
<td>42 (10)</td>
<td>48 (11)</td>
</tr>
<tr>
<td>Original DVT†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>67</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>47</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>Unknown</td>
<td>6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Duration of follow-up,</td>
<td>mean (range), mo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55.1 (0.2-99.2)</td>
<td>55.0 (2.0-97.3)</td>
<td>59.1 (18.3-97.2)</td>
<td>28.0 (2.9-62.4)</td>
</tr>
<tr>
<td>Deaths</td>
<td>17</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Treatment failures (PPS)</td>
<td>6</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

*PPS indicates postphlebitic syndrome; VVI, venous valvular incompetence; GCS, graduated compression stocking; and DVT, deep venous thrombosis.

†Asymptomatic original DVT found on routine postoperative venography; symptomatic original DVT presented with symptoms suggestive of DVT.
who do not meet our criteria for PPS 1 year after proximal DVT, regardless of the presence or absence of venous valvular incompetence, stockings are not justified. This conclusion is based on the extremely low rate of development of PPS in the patients enrolled in studies 1 and 2 (7/167 = 4.2%; 95% CI, 1.7%-8.4%). We were unable to demon-
strate a benefit of graduated compression stockings in patients with established PPS. Although this conclusion is limited by the relatively small numbers, the results do suggest that the benefit of stockings is limited.

Our study could be criticized because the use of “oversized” placebo stockings might have made some patients aware that they were being treated with a placebo. However, we excluded patients who had previously worn stockings, reducing the risk of unblinding. In addition, if patients were systematically unblinded we would have expected a bias in favor of preferring the “active” stocking and an increase in treatment failures in the placebo group, neither of which was seen.

Our results appear to conflict with a previous random-
dized trial in which patients with DVT were random-
ized (at the time of DVT) to either a stocking or no treat-
ment. However, that study differs in 2 ways from ours: first, no placebo was used that might have biased the as-
essment and, second, the definition of the PPS and treat-
ment failures were different. In our study, we used a defi-
nition that focuses on lifestyle and quality of life, whereas in the previous study, a symptom score, which included asymptomatic findings that might lack clinical relevance, was generated based on signs as well as symp-
toms of PPS.

Based on our study results and clinical experience, we recommend the following strategy in patients with acute DVT. Empirically, to relieve acute pain and swell-
ing, simple maneuvers, such as elevating the leg and avoiding aggravating positions and activities, should be strongly recommended. We advise against the routine use of stock-
nings shortly after DVT except under unusual circum-
stances because they can be difficult to put on in symp-
tomatic patients, they are likely to fit poorly once the acute swelling dissipates, and, in our experience, the acute symp-
toms resolve within 1 to 3 months after DVT. We limit stocking therapy to those with severe symptoms and tend to use “lightweight” stockings. We also believe waiting for 1 year is reasonable since none of our patients devel-
oped substantial symptomatic worsening and none de-
veloped severe sequelae, such as skin ulceration. If pa-
ients do not have symptomatic PPS at 1 year, stockings can be avoided and the patients reassured that their sub-
sequent risk of symptomatic worsening is very low. In symp-
tomatic patients with PPS, we recommend a trial of properly fitted graduated compression stockings since although we were unable to demonstrate a clear benefit, the study did not have enough power to detect a clin-
ically important improvement in symptoms. In addition, our clinical experience, as well as a limited number of published studies, suggests that some symptomatic pa-
ients benefit from stockings. Finally, patients for whom stockings fail or who are intolerant of stockings, should undergo a trial of intermittent compression therapy with an extremity pump, which we have found beneficial in a

significant proportion (approximately 75%) of pa-

Accepted for publication February 22, 2001.

Dr Ginsberg is a recipient of a Career Investigator Award of the Heart and Stroke Foundation of Ontario, sup-
ported by a Grant-In-Aid of the National Health Research Department Program of Health and Welfare Canada (grant 6606-161-60).

We thank Ju zo, Inc, Cuyahoga Falls, Ohio, for pro-

REFERENCES

2. Ginsberg JS. Prevention of the post-thrombotic syndrome. In: Ginsberg JS, Ke-
aron C, Hirsh J, eds. Critical Decisions in Thrombosis and Hemostasis. Burling-
3. Cronin JJ, Leen V. Recurrent deep venous thrombosis: limitation of US. Radi-
ology. 1989;170:739-742.
4. Mantoni M. Deep venous thrombosis: longitudinal study with duplex US. Radi-
8. Elliot MS, Immelmen EJ, Jeffery P, et al. A comparative randomized trial of hepar-
in or streptokinase in the treatment of the acute proximal venous thrombo-
10. Trubestein G. Can thrombolytics prevent post-phlebitic syndrome and throm-
12. Pierson S, Pierson D, Svallov RT, Johnson G. Efficacy of graduated elastic com-
13. Jones NAG, Webb PJ, Rees RI, Kakkar VV. A physiological study of elastic com-
14. Gandhi DB, Palmer JR, Lewis B, Schradman IG. Clinical comparison of elastic sup-
15. Akroyd JS, Browse NW. The investigation and surgery of the post thrombotic syn-
16. Brandjes DPM, Buller HR, Heijbroek H, et al. Randomised trial of effect of com-
pression stockings in patients with symptomatic proximal-vein thrombosis. Lan-
18. Ginsberg JS, Shin A, Turpie AG, Hirsh J. Detection of previous deep vein throm-
bus and postphlebitic syndrome with Doppler ultrasonography and photo-
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospec-